An in silico approach for the identification of inhibitors against Acetylcholinesterase

Medicinal Chemistry Research

Volumn 21, Issue 10, 2012, Pages 2779-2787

  Remya, C ^a   Dileep, K V ^a   Tintu, I ^a   Variyar, E J ^a   Sadasivan, C ^a  

^a KANNUR UNIVERSITY   (India)

Author keywords

Acetylcholinesterase; Donepezil; Induced fit docking; Virtual screening

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; UNCLASSIFIED DRUG; ZINC 02040474; ZINC 08750211; ZINC 11709541; ZINC 13802320; ZINC 49718337;

ARTICLE; BINDING AFFINITY; COMPUTER MODEL; COMPUTER PROGRAM; DATA BASE; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG STRUCTURE; INDUCED FIT DOCKING; MOLECULAR DOCKING; MOLECULAR MODEL; PHYSICAL CHEMISTRY; PREDICTED ACTIVITY SPECTRA FOR SUBSTANCE; VIRTUAL REALITY;

EID: 84866419359     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9814-y     Document Type: Article

References (42)

1. Barnard EA (1974) Neuromuscular transmission-enzymatic destruction of acetylcholine. In: Hubbard JI (ed) The peripheral nervous system. Plenum Press, New York, pp 201-224
2. Bartus RT, Dean RL III, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217: 408-414
3. Bergmann F, Wilson IB, Nachmansohn D (1950) The inhibitory effect of stilbamidine, curare and related compounds and its relationship to the active groups of acetylcholine esterase. Action of stilbamidine upon nerve impulse conduction. Biochim Biophys Acta 6:217-224
4. Castro A, Martinez A (2006) Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr Pharm Des 12: 4377-4387
5. Changeux JP (1966) Responses of acetylcholinesterase from Torpedo marmorata to salts and curarizing drugs. Mol Pharmacol 2:369-392
6. da Silva CHTP, Campo VL, Carvalho I, Taft CA (2006) Molecular modeling, docking and ADMET studies applied to the design of a novel hybrid for treatment of alzheimer's disease. J Mol Graphics Modell 25:169-175
7. Froede HC, Wilson IB (1971) Acetylcholinesterase, in: Boyer PD (ed) The enzymes, vol 5. Academic Press, New York, pp 87-114
8. Garcia-Palomero E, Munoz P, Usaan P, Garcia P, Delgado E, De Austria C, Valenzuela R, Rubio L, Medina M, Martinez A (2008) Potent beta-amyloid modulators. Neurodegener Dis 5: 153-156
9. Giacobini E (2003) Cholinergic function and Alzheimer's disease. Int J Geriatr Psychiatr 18:S1-S5
10. Giacobini E, Zhu XD, Williams E, Sherman KA (1996) The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 35:205-211
11. Goedert M, Spillantini MG (2006) A century of Alzheimer's disease. Science 314:777-781
12. Greenblatt HM, Dvir H, Silman I, Sussman JL (2003) Acetylcholinesterase: a multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer's disease. J Mol Neurosci 20:369-384
13. Jann MW (2000) Rivastigmine, a new- generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 20:1-12
14. Kasa P, Papp H, Kasa P Jr, Torok I (2000) Donepezil dosedependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain. Neuroscience 101:89-100
15. Kryger G, Silman I, Sussman JL (1999) Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure 7:297-307
16. Kurz AJ (1998) The therapeutic potential of tacrine. Neural Transm Suppl 54:295-299
17. Lagunin A, Stepanchikova A, Filimonov D, Poroikov V (2000) PASS: prediction of activity spectra for biologically active substances. Bioinformatics 16:747-748
18. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 46:3-26
19. Luttmann E, Linnemann E, Fels G (2002) Galantamine as bisfunctional ligand for the acetylcholinesterase. J Mol Model 8: 208-216
20. Marwaha A, Goel RK, Mahajan MP (2007) PASS-predicted design, synthesis and biological evaluation of cyclic nitrones as nootropics. Bioorg Med Chem Lett 17:5251-5255
21. Mizutani MY, Itai A (2004) Efficient method for high throughput virtual screening based on flexible docking; discovery of novel acetylcholinesterase inhibitors. J Med Chem 47:4818-4828
22. Mooser G, Sigman DS (1974) Ligand binding properties of acetylcholinesterase determined with fluorescent probes. Biochemistry 13:2299-2307
23. Nachmansohn D, Wilson IB (1951) The enzymic hydrolysis and synthesis of acetylcholine. Adv Enzymol 12:259-339
24. Nightingale SL (1997) Donepezil approved for treatment of Alzheimer's disease. JAMA 277:10
25. Pajouhesh H, Lenz GR (2005) Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2:541-553
26. Perry EK, Perry RH, Blessed G, Tomlinson BE (1977) Necropsy evidence of central cholinergic details in senile dementia. The Lancet i:189
27. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2:1457-1459
28. Radić Z, Pickering NA, Vellom DC, Camp S, Taylor P (1993) Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors. Biochemistry 32:12074-12084
29. Recanatini M, Valenti P (2004) Acetylcholinesterase inhibitors as a starting point towards improved Alzheimer's disease therapeutics. Curr Pharm Des 10:3157-3166
30. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ (2003) Memantine in moderate to severe Alzheimer's disease. N Engl J Med 348:1333-1341
31. Reyes AE, Chacon MA, Dinamarca MC, Cerpa W, Morgan C, Inestrosa NC (2004) Acetylcholinesterase-Abeta complexes are more toxic than Abeta fibrils in rat hippocampus: effect on rat beta-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss. Am J Pathol 164:2163-2174
32. Roberson ED, Mucke L (2006) 100 years and counting: prospects for defeating Alzheimer's disease. Science 314:781-784
33. Robinson DM, Keating GM (2006) Memantine: a review of its use in Alzheimer's disease. Drugs 66:1515-1534
34. Rosenberry TL (1975) Acetylcholinesterase. Adv Enzymol 43: 103-218
35. Selkoe DJ (2001) Alzheimer's disease: genes, proteins and therapy. Phys Rev 81:741-766
36. Small DH (2005) Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors. Expert Opin Emerg Drugs 10:817-825
37. Sopkova-de Oliveira Santos J, Lesnard A, Agondanou J-H, Dupont N, Godard A-M, Stiebing S, Rochais C, Fabis F, Dallemagne P, Bureau R, Rault S (2010) Virtual screening discovery of new acetylcholinesterase derived from CERMN chemical library. J Chem Inf Model 50:422-428
38. Sugimoto H (2001) Donepezil hydrochloride: a treatment drug for Alzheimer's disease. Chem Rec 1:63-73
39. Terry AV Jr, Buccafusco JJ (2003) The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306:821-827
40. Vellom DC, Radić Z, Li Y, Pickering NA, Camp S, Taylor P (1993) Amino acid residues controlling acetylcholinesterase and butyrylcholinesterase specificity. Biochemistry 32:12-17
41. Zaheer-ul-hag, Halima SA, Uddina R, Madura JD (2010) Benchmarking docking and scoring protocol for the identification of potential acetylcholinesterase inhibitors. J Mol Graph Model 28:870-882
42. Zarotsky V, Sramek JJ, Cutler NR (2003) Galantamine hydrobromide: an agent for Alzheimer's disease. Am J Health Syst Pharm 60:446-452